<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="4858"><DrugName>milnacipran</DrugName><DrugNamesKey><Name id="42840501">Dalcipran</Name><Name id="42911314">Impulsor</Name><Name id="42840499">Ixel</Name><Name id="43083608">Ixel Cap</Name><Name id="42971368">Joncia</Name><Name id="42915352">Lixel</Name><Name id="42899939">Savella</Name><Name id="42768180">Toledomin</Name><Name id="42756953">milnacipran</Name><Name id="42840502">milnacipran hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>milnacipran</Value><Types><Type>INN</Type></Types></Name><Name><Value>F-2207</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>F-2641</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Toledomin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ixel</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Dalcipran</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>milnacipran hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>Savella</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Impulsor</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Lixel</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Joncia</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Ixel Cap</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>92623-85-3</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>101152-94-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19087">Pierre Fabre SA</CompanyOriginator><CompaniesPrimary><Company id="15280">Bukwang Pharmaceutical Co Ltd</Company><Company id="17408">Janssen Pharmaceutical KK</Company><Company id="1088700">Allergan plc</Company><Company id="19087">Pierre Fabre SA</Company><Company id="14303">Asahi Kasei Pharma Corp</Company></CompaniesPrimary><CompaniesSecondary><Company id="16198">Forest Laboratories Inc</Company><Company id="17403">Janssen Inc</Company><Company id="23891">Cypress Bioscience Inc</Company><Company id="26494">Sanofi-Synthelabo</Company><Company id="26495">Sanofi (pre-1999)</Company></CompaniesSecondary><CrossReferences><SourceEntity id="4858" type="Drug"><TargetEntity id="90753" type="siDrug">Milnacipran hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1088700" type="Company"><TargetEntity id="5040050523" type="organizationId">Allergan plc</TargetEntity></SourceEntity><SourceEntity id="14303" type="Company"><TargetEntity id="4297795556" type="organizationId">Asahi Kasei Pharma Corp</TargetEntity></SourceEntity><SourceEntity id="15280" type="Company"><TargetEntity id="4295882153" type="organizationId">Bukwang Pharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="16198" type="Company"><TargetEntity id="4295904015" type="organizationId">Forest Laboratories Inc</TargetEntity></SourceEntity><SourceEntity id="17403" type="Company"><TargetEntity id="5033197841" type="organizationId">Janssen Inc</TargetEntity></SourceEntity><SourceEntity id="17408" type="Company"><TargetEntity id="4298195092" type="organizationId">Janssen Pharmaceutical KK</TargetEntity></SourceEntity><SourceEntity id="19087" type="Company"><TargetEntity id="4296343109" type="organizationId">Pierre Fabre SA</TargetEntity></SourceEntity><SourceEntity id="23891" type="Company"><TargetEntity id="4295913115" type="organizationId">Cypress Bioscience Inc</TargetEntity></SourceEntity><SourceEntity id="26494" type="Company"><TargetEntity id="5000326934" type="organizationId">Sanofi Synthelabo Caraibes SARL</TargetEntity></SourceEntity><SourceEntity id="26495" type="Company"><TargetEntity id="4295866846" type="organizationId">Thales SA</TargetEntity></SourceEntity><SourceEntity id="1295" type="ciIndication"><TargetEntity id="10029223" type="MEDDRA"/><TargetEntity id="D009437" type="MeSH"/><TargetEntity id="-533466818" type="omicsDisease"/><TargetEntity id="14" type="siCondition"/></SourceEntity><SourceEntity id="192" type="ciIndication"><TargetEntity id="K58" type="ICD10"/><TargetEntity id="10023003" type="MEDDRA"/><TargetEntity id="D043183" type="MeSH"/><TargetEntity id="-716973018" type="omicsDisease"/><TargetEntity id="397" type="siCondition"/></SourceEntity><SourceEntity id="2527" type="ciIndication"><TargetEntity id="M79.7" type="ICD10"/><TargetEntity id="10048439" type="MEDDRA"/><TargetEntity id="D005356" type="MeSH"/><TargetEntity id="-1947347836" type="omicsDisease"/><TargetEntity id="1156" type="siCondition"/></SourceEntity><SourceEntity id="3221" type="ciIndication"><TargetEntity id="10003988" type="MEDDRA"/><TargetEntity id="D001416" type="MeSH"/><TargetEntity id="-1072041800" type="omicsDisease"/><TargetEntity id="4128" type="siCondition"/></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"/><TargetEntity id="D003863" type="MeSH"/><TargetEntity id="-508468160" type="omicsDisease"/><TargetEntity id="53" type="siCondition"/></SourceEntity><SourceEntity id="3" type="Action"><TargetEntity id="235" type="Mechanism">5-HT Reuptake Inhibitors</TargetEntity></SourceEntity><SourceEntity id="285" type="Action"><TargetEntity id="63" type="Mechanism">Norepinephrine Reuptake Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Depression - Bulgaria - Dec-1996</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="2527">Fibromyalgia</Indication><Indication id="93">Depression</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1295">Neuropathic pain</Indication><Indication id="192">Irritable bowel syndrome</Indication><Indication id="3221">Back pain</Indication></IndicationsSecondary><ActionsSecondary><Action id="285">Norepinephrine uptake inhibitor</Action><Action id="2941">Antidepressant</Action><Action id="3">5-HT uptake inhibitor</Action><Action id="5557">Muscle relaxant</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="751">Film coating</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N6A4</Code><Name>SSRI antidepressants</Name></Ephmra><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra><Ephmra><Code>N6A5</Code><Name>SRNI antidepressants</Name></Ephmra><Ephmra><Code>M3</Code><Name>MUSCLE RELAXANTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-04-23T14:15:36.000Z</LastModificationDate><ChangeDateLast>2019-04-24T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19087" linkType="Company"&gt;Pierre Fabre&lt;/ulink&gt; has developed and launched milnacipran (Savella; Ixel; Toledomin), an oral selective serotonin and norepinephrine reuptake inhibitor (SNRI). The product is indicated in France and Japan, as Ixel and Toledomin, respectively, for the treatment of severe depression  [&lt;ulink linkID="1254721" linkType="Reference"&gt;1254721&lt;/ulink&gt;], [&lt;ulink linkID="1346524" linkType="Reference"&gt;1346524&lt;/ulink&gt;]. &lt;ulink linkID="23891" linkType="Company"&gt;&lt;/ulink&gt;The product is also indicated in the US as Savella, where it is marketed by US licensee  &lt;ulink linkID="1088700" linkType="Company"&gt;Allergan&lt;/ulink&gt; (formerly  &lt;ulink linkID="16198" linkType="Company"&gt;Forest&lt;/ulink&gt;, formerly &lt;ulink linkID="1088700" linkType="Company"&gt;Actavis&lt;/ulink&gt;),  for the management of fibromyalgia [&lt;ulink linkID="1639309" linkType="Reference"&gt;1639309&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 1997, milnacipran was launched as Ixel in France  by Pierre Fabre for the treatment of severe depression   [&lt;ulink linkID="264142" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1346524" linkType="Reference"&gt;1346524&lt;/ulink&gt;]. In  October 2000, the drug was   launched for depression in Japan  by licensees &lt;ulink linkID="14303" linkType="Company"&gt;Asahi Kasei&lt;/ulink&gt; and  &lt;ulink linkID="17408" linkType="Company"&gt;Janssen Pharmaceutical&lt;/ulink&gt;  [&lt;ulink linkID="348868" linkType="Reference"&gt;348868&lt;/ulink&gt;], [&lt;ulink linkID="393239" linkType="Reference"&gt;393239&lt;/ulink&gt;], [&lt;ulink linkID="1254721" linkType="Reference"&gt;1254721&lt;/ulink&gt;]. The product has not  been launched in the US for depression.&lt;/para&gt;&lt;para&gt;In April 2009, milnacipran was launched in the US by Forest for fibromyalgia  [&lt;ulink linkID="1008295" linkType="Reference"&gt;1008295&lt;/ulink&gt;], [&lt;ulink linkID="1574106" linkType="Reference"&gt;1574106&lt;/ulink&gt;]. In June 2008, Pierre Fabre filed for European approval for fibromyalgia [&lt;ulink linkID="955053" linkType="Reference"&gt;955053&lt;/ulink&gt;], [&lt;ulink linkID="955405" linkType="Reference"&gt;955405&lt;/ulink&gt;]. In July 2009, the CHMP of the EMEA recommended against approval  [&lt;ulink linkID="1028135" linkType="Reference"&gt;1028135&lt;/ulink&gt;]. By November 2009, a re-examination of the opinion had been conducted, and the CHMP confirmed the refusal of the marketing authorization at that time [&lt;ulink linkID="1086846" linkType="Reference"&gt;1086846&lt;/ulink&gt;]; by January 2013, development  of the drug had been discontinued in the UK for the treatment of fibromyalgia, and no further development in Europe had been reportedÂ [&lt;ulink linkID="1353365" linkType="Reference"&gt;1353365&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was previously developed for other pain indications. In April 2011, a phase IV trial for pain due to osteoarthritis was planned; however, no further development has been reported [&lt;ulink linkID="1199984" linkType="Reference"&gt;1199984&lt;/ulink&gt;]. In November 2011, a phase II trial to treat the pain symptoms of irritable bowel syndrome (IBS) began; however by November 2013, the study had been terminated  [&lt;ulink linkID="1340951" linkType="Reference"&gt;1340951&lt;/ulink&gt;]. By August 2010, Forest was conducting a phase III trial for back pain, and in October 2010, the company initiated a clinical trial for idiopathic neuropathic pain [&lt;ulink linkID="1175415" linkType="Reference"&gt;1175415&lt;/ulink&gt;], [&lt;ulink linkID="1175425" linkType="Reference"&gt;1175425&lt;/ulink&gt;]. In August 2014, data were published from patients with lumbosacral disc disease, including low back pain [&lt;ulink linkID="1639319" linkType="Reference"&gt;1639319&lt;/ulink&gt;]. However, in December 2016, a trial for idiopathic neuropathic pain was terminated due to poor enrollment [&lt;ulink linkID="1175425" linkType="Reference"&gt;1175425&lt;/ulink&gt;], and in January 2017, a phase III trial for back pain was withdrawn with no patients enrolled [&lt;ulink linkID="1175415" linkType="Reference"&gt;1175415&lt;/ulink&gt;]; no further development for those indications has been reported.&lt;/para&gt;&lt;para&gt;Pierre Fabre and Forest have also developed &lt;ulink linkID="54889" linkType="Drug"&gt;levomilnacipran&lt;/ulink&gt;,  the (1S,2R)-isomer of milnacipran.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In August 2003, Cypress was issued &lt;ulink linkID="PA3111049" linkType="Patent"&gt;US-06602911&lt;/ulink&gt; by the USPTO. The patent covers methods of treating fibromyalgia with milnacipran in various dosages and formulations [&lt;ulink linkID="500170" linkType="reference"&gt;500170&lt;/ulink&gt;]; it had been scheduled to expire in 2021, however the patent was granted patent term extension taking expiry to January 2023 [&lt;ulink linkID="1120976" linkType="Reference"&gt;1120976&lt;/ulink&gt;], [&lt;ulink linkID="1480527" linkType="Reference"&gt;1480527&lt;/ulink&gt;]. In October 2003, Cypress was awarded &lt;ulink linkID="PA3129959" linkType="Patent"&gt;US-06635675&lt;/ulink&gt;, covering the use of milnacipran for the treatment of chronic fatigue syndrome and expiring in 2021 [&lt;ulink linkID="510251" linkType="reference"&gt;510251&lt;/ulink&gt;]. Hatch-Waxman exclusivity expired in January 2014 [&lt;ulink linkID="1301478" linkType="Reference"&gt;1301478&lt;/ulink&gt;]. Forest also licensed &lt;ulink linkID="PA5669152" linkType="Patent"&gt;US-07888342&lt;/ulink&gt; and &lt;ulink linkID="PA3483138" linkType="Patent"&gt;US-07994220&lt;/ulink&gt; from &lt;ulink linkID="DOL1000090" linkType="Company"&gt;Royalty Pharma&lt;/ulink&gt;, which expire in November 2021 and September 2029, respectively [&lt;ulink linkID="1480527" linkType="Reference"&gt;1480527&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2017, Allergan brought infringement actions concerning the '911, '342 and '220 patent in the US District Court against &lt;ulink linkID="30808" linkType="Company"&gt;Strides Pharma&lt;/ulink&gt;;  in April 2018, the company entered into a settlement agreement with Strides and the case was dismissed [&lt;ulink linkID="2121173" linkType="Reference"&gt;2121173&lt;/ulink&gt;]. In July 2018, Strides Pharma received tentative approval from the FDA for its Paragraph IV filing of milnacipran hydrochloride generic tablets in 12.5, 25, 50 and 100 mg strengths [&lt;ulink linkID="2051716" linkType="Reference"&gt;2051716&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, Forest filed lawsuits against several companies, including &lt;ulink linkID="22353" linkType="Company"&gt;Apotex&lt;/ulink&gt;, Hetero USA, &lt;ulink linkID="21932" linkType="Company"&gt;Lupin&lt;/ulink&gt;, &lt;ulink linkID="18439" linkType="Company"&gt;Mylan&lt;/ulink&gt;, &lt;ulink linkID="28256" linkType="Company"&gt;Par&lt;/ulink&gt; and &lt;ulink linkID="29267" linkType="Company"&gt;Ranbaxy&lt;/ulink&gt;, alleging infringement  of US-06602911, US-07888342 and US-07994220 following ANDA filings with Paragraph IV certifications from all of the companies [&lt;ulink linkID="1480527" linkType="Reference"&gt;1480527&lt;/ulink&gt;]. At that time, Mylan believed it was first to file its ANDA and anticipated 180-day exclusivity [&lt;ulink linkID="1480881" linkType="Reference"&gt;1480881&lt;/ulink&gt;]. In October 2013, Forest filed an additional lawsuit against First Time US Generics LLC alleging infringement of patents covering milnacipran including US-06602911, US-07888342 and US-07994220 following First Timeâs ANDA filing [&lt;ulink linkID="1483672" linkType="Reference"&gt;1483672&lt;/ulink&gt;]. By February 2014,  Forest had a filed a lawsuit against &lt;ulink linkID="1027030" linkType="Company"&gt;Amneal Pharmaceutical&lt;/ulink&gt;, alleging patent infringement following an ANDA filing  [&lt;ulink linkID="1745004" linkType="Reference"&gt;1745004&lt;/ulink&gt;]. In March 2014, Forest and Royalty voluntarily dismissed all claims that they had filed against &lt;ulink linkID="28696" linkType="Company"&gt;Sandoz&lt;/ulink&gt;, and a trial was  set for January 2016 for all the remaining pending actions. In May 2014, Forest and Royalty agreed a settlement with First Time US Generics, licensing First Time the right to launch its generic version 6  months prior to the expiration of US-06602911, US-07888342 and US-07994220 including any extensions and/or pediatric exclusivities or the date First Time received final ANDA approval, whichever was the later [&lt;ulink linkID="1589882" linkType="Reference"&gt;1589882&lt;/ulink&gt;]. In December 2014,  Forest and Royalty agreed a settlement with Ranbaxy. In April 2015, the defendants filed a motion to dismiss for lack of standing. Later in April 2015, Forest settled its litigation with Par, permitting Par to launch its generic 6  months prior to the expiration of the 911', 342' and 220' patents including any extensions and/or pediatric exclusivities or the date Par received final ANDA approval, whichever was the later [&lt;ulink linkID="1745004" linkType="Reference"&gt;1745004&lt;/ulink&gt;]. In October 2015, Lupin received tentative FDA approval for its generic milnacipran tablets (12.5, 50, 75 and 100 mg) [&lt;ulink linkID="1704502" linkType="Reference"&gt;1704502&lt;/ulink&gt;]. In December 2015,  Forest and Royalty agreed a settlement with Hetero, and in January 2016, settlement agreements were reached with both Amneal and Apotex; the defendants under these agreements were permitted to enter the market with their generic products in March 19, 2026. Later in January 2016, a bench trial concluded and a post-trial briefing was set to conclude in April 26, 2016 [&lt;ulink linkID="1745004" linkType="Reference"&gt;1745004&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2014, Forest received notification of  &lt;ulink linkID="29326" linkType="Company"&gt;Glenmark&lt;/ulink&gt;'s filing of an ANDA for a generic version of Savella tablets [&lt;ulink linkID="1804799" linkType="Reference"&gt;1804799&lt;/ulink&gt;].In December 2015, litigation with Glenmark was settled related to an ANDA filing from Glenmark for generic versions of 12.5 milligram, 25 milligram, 50 milligram, and 100 milligram tablets. Under the terms of the agreement, Glenmark would have the option to market and distribute its version or an authorized generic version. Other terms of the agreement were confidential [&lt;ulink linkID="1723610" linkType="Reference"&gt;1723610&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;SPCs on &lt;ulink linkID="IN1100327" linkType="Patent"&gt;EP-00068999&lt;/ulink&gt; expired in Austria and Luxembourg in June 2007, and on &lt;ulink linkID="IN1186777" linkType="Patent"&gt;FR-02508035&lt;/ulink&gt; in France in June 2006.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;&lt;ulink linkID="IN1222277" linkType="Patent"&gt;JP-63023186&lt;/ulink&gt; expired in June 2007.&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Fibromyalgia syndrome&lt;/subtitle&gt;In December 2007, an NDA was filed by Forest and Cypress for the treatment of fibromyalgia [&lt;ulink linkID="864011" linkType="Reference"&gt;864011&lt;/ulink&gt;]. In February 2008, the FDA accepted the NDA for review [&lt;ulink linkID="878626" linkType="Reference"&gt;878626&lt;/ulink&gt;]. In October 2008, the FDA advised that it would not be able to take final action on the NDA by the scheduled PDUFA date. No additional information was required, but a question related to the clinical data in the submission required confirmation [&lt;ulink linkID="953722" linkType="Reference"&gt;953722&lt;/ulink&gt;]. In January 2009, milnacipran was approved for the management of fibromyalgia in the US [&lt;ulink linkID="976636" linkType="Reference"&gt;976636&lt;/ulink&gt;]; in March 2009, the companies expected the drug to be made available after a minor cosmetic formulation change was submitted for FDA approval [&lt;ulink linkID="989556" linkType="Reference"&gt;989556&lt;/ulink&gt;]. In April 2009,  the FDA approved this change and the drug was launched later that month [&lt;ulink linkID="1001453" linkType="Reference"&gt;1001453&lt;/ulink&gt;], [&lt;ulink linkID="1008295" linkType="Reference"&gt;1008295&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Fibromyalgia syndrome&lt;/subtitle&gt;In June 2008, Pierre Fabre  filed the compound for European approval [&lt;ulink linkID="955405" linkType="Reference"&gt;955405&lt;/ulink&gt;]. In July 2009, the CHMP of the EMEA recommended against approval of the drug [&lt;ulink linkID="1028135" linkType="Reference"&gt;1028135&lt;/ulink&gt;]. By November 2009, a re-examination of the opinion had been requested; however, the CHMP again recommended refusal of marketing authorization [&lt;ulink linkID="1086846" linkType="Reference"&gt;1086846&lt;/ulink&gt;]. By January 2013, development  of the drug had been discontinued in the UK for the treatment of fibromyalgia, and no further development in Europe had been reportedÂ [&lt;ulink linkID="1353365" linkType="Reference"&gt;1353365&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Depression&lt;/subtitle&gt;In December 1996, the drug was approved in Bulgaria, and launch was presumed to follow shortly therafter [&lt;ulink linkID="1450303" linkType="Reference"&gt;1450303&lt;/ulink&gt;]. Milnacipran (as Ixel) was first launched by Pierre Fabre in France in June 1997, for the treatment of depression  [&lt;ulink linkID="1346524" linkType="Reference"&gt;1346524&lt;/ulink&gt;],   [&lt;ulink linkID="348868" linkType="reference"&gt;348868&lt;/ulink&gt;], [&lt;ulink linkID="393239" linkType="reference"&gt;393239&lt;/ulink&gt;]. In April 1999, the drug was launched in Austria. Since that time, the drug had been made available in other European countries [&lt;ulink linkID="1048441" linkType="Reference"&gt;1048441&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;&lt;subtitle&gt;Depression&lt;/subtitle&gt;In  October 2000, milnacipran was launched by Japanese licensees Jannsen Kyowa and Asahi Kasei in Japan for depression  [&lt;ulink linkID="348868" linkType="reference"&gt;348868&lt;/ulink&gt;], [&lt;ulink linkID="393239" linkType="reference"&gt;393239&lt;/ulink&gt;], [&lt;ulink linkID="1254721" linkType="Reference"&gt;1254721&lt;/ulink&gt;]. In November 2008, Asahi Kasei launched 12.5 and 50 mg doses of milnacipran [&lt;ulink linkID="1254722" linkType="Reference"&gt;1254722&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;From 2000 to 2003, launch took place in  Central America [&lt;ulink linkID="1048441" linkType="Reference"&gt;1048441&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;From 2000 to 2003, launch took place in  South America [&lt;ulink linkID="1048441" linkType="Reference"&gt;1048441&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;In May 1999, launch took place in  countries of the Middle East [&lt;ulink linkID="1048441" linkType="Reference"&gt;1048441&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 1999, launch took place in Lebanon [&lt;ulink linkID="1048441" linkType="Reference"&gt;1048441&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;From 2000 to 2003, launch took place in  North Africa [&lt;ulink linkID="1048441" linkType="Reference"&gt;1048441&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;It was assumed that the drug was launched in Taiwan shortly after its approval there  for severe depression in August 2011 [&lt;ulink linkID="1548001" linkType="Reference"&gt;1548001&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, the drug was approved in Australia for fibromyalgia, under the tradename Joncia [&lt;ulink linkID="1241781" linkType="Reference"&gt;1241781&lt;/ulink&gt;]. By March 2015, the drug had not yet been launched in Australia [&lt;ulink linkID="1639346" linkType="Reference"&gt;1639346&lt;/ulink&gt;]. By July 2017, the drug was presumed to have been made available in Australia [&lt;ulink linkID="2065992" linkType="Reference"&gt;2065992&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;The US label for Savella carries a black box warning highlighting the risk for increased suicidal thoughts [&lt;ulink linkID="1639309" linkType="Reference"&gt;1639309&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In February 2010, a phase IV, multicenter, randomized, double-blind, placebo-controlled, switch study (&lt;ulink linkID="64593" linkType="Protocol"&gt;NCT01077375&lt;/ulink&gt;; MLN-MD-28) was initiated in the US to evaluate the safety, tolerability and efficacy of milnacipran (100 to 200 mg/day) in fibromyalgia patients (estimated n = 100) with an inadequate response to &lt;ulink linkID="5907" linkType="Drug"&gt;duloxetine&lt;/ulink&gt;. The primary endpoint was Patient Global Impression of Change (PGIC), assessed at 6 and 10 weeks (or early termination) post-randomization. The study was expected to complete in March 2011 [&lt;ulink linkID="1124451" linkType="Reference"&gt;1124451&lt;/ulink&gt;], [&lt;ulink linkID="1124497" linkType="Reference"&gt;1124497&lt;/ulink&gt;]. In November 2011, results were presented at the ACR/ARHP Annual Meeting in Chicago, IL. Patients were randomized in a 4: 1 ratio to receive double-blind milnacipran (100 mg/day; n = 86) or placebo (n = 21) for 10 weeks. After a direct switch from duloxetine to milnacipran, patients, at week 10, showed improvements in each PROMIS computer adaptive test domain. Milnacipran-treated patients experienced significant reductions in fatigue and wake disturbance  and non-significant gains in physical function, and discretionary social activity [&lt;ulink linkID="1228508" linkType="Reference"&gt;1228508&lt;/ulink&gt;]. Further data were presented at the same conference. At week 10, 32.9% of patients dosed with milnacipran were patient global impression of change responders (primary endpoint) and the overall milnacipran group had a mean decrease from baseline in visual analog score (VAS) pain of 12.3 mm. Of the patients treated with milnacipran, 34.2% showed &amp;gt;/= 30% improvement in VAS pain while 29.1% patients showed &amp;gt;/= 40% improvement and 25.3% showed &amp;gt;/= 50%  improvement [&lt;ulink linkID="1231939" linkType="Reference"&gt;1231939&lt;/ulink&gt;]. In May 2012,  further data were presented at the 31st Annual APS Meeting in Honolulu, HI. There was an improvement of 14% (7.8) in the fibromyalgia impact questionnaire revised (FIQR) scores for patients who switched to milnacipran and a small improvement in multiple ability self-report questionnaire (MASQ) scores. Those patients switched to placebo also had improved FIQR scores (1.4) but a lower MASQ score [&lt;ulink linkID="1286309" linkType="Reference"&gt;1286309&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2009, a phase IV multicenter, randomized, double-blind, placebo-controlled study (&lt;ulink linkID="61975" linkType="Protocol"&gt;NCT01014585&lt;/ulink&gt;; MLN-MD-27) was initiated in the US, to evaluate the durability of effect of milnacipran  in patients  (n = 425) receiving long-term milnacipran treatment. The primary endpoint was loss of therapeutic response (LTR), defined as a &amp;lt;30% reduction in Visual Analog Scale (VAS) pain score from pre-milnacipran exposure or a worsening of fibromyalgia requiring (in the judgment of the investigator), an alternative treatment. The study was completed in May 2010 [&lt;ulink linkID="1124451" linkType="Reference"&gt;1124451&lt;/ulink&gt;], [&lt;ulink linkID="1124470" linkType="Reference"&gt;1124470&lt;/ulink&gt;]. In November 2011, results were presented from the study at the ACR/ARHP Annual Meeting in Chicago, IL. Patients were treated with milnacipran at up to 200 mg/day for 4 weeks. Significantly shorter LTR (50 days) was observed in patients treated with placebo (milnacipran withdrawn patients; n = 50) when compared with milnacipran-treated patients (n = 100). Â LTR criteria were met by 64% of patients in whom milnacipran was withdrawn when compared with 35% of patients in whom milnacipran was continued [&lt;ulink linkID="1228485" linkType="Reference"&gt;1228485&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Fibromyalgia syndrome&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In December 2013, data were published from a 3-year, open-label, flexible-dosing study demonstrating sustained symptom improvements in fibromyalgia patients who received up to 3.25 years of milnacipran  [&lt;ulink linkID="1639343" linkType="Reference"&gt;1639343&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2011, pooled data from three phase III, randomized, placebo-controlled studies in patients with fibromyalgia were presented at the 30th Annual Scientific Meeting of the APS in Austin, TX. Significant improvements were observed in the milnacipran group in multidimensional fatigue inventory (MFI) total score at the 3-month endpoint. Milnacipran 200 mg/day treatment showed significant improvements in all MFI subscale scores versus placebo and milnacipran 100 mg/day significantly improved general fatigue, physical fatigue and reduced motivation subscale scores versus placebo. Reduced pain visual analog scores (VAS) were observed in milnacipran-treated patients [&lt;ulink linkID="1216092" linkType="Reference"&gt;1216092&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2008, a phase III multicenter, randomized, open-label, active controlled study (&lt;ulink linkID="37130" linkType="Protocol"&gt;NCT00797797&lt;/ulink&gt;; MLN-MD-15) was initiated in the US, to evaluate the safety, tolerability, and efficacy of milnacipran  in combination with &lt;ulink linkID="17814" linkType="Drug"&gt;pregabalin&lt;/ulink&gt; in the treatment of fibromyalgia. Patients  (n = 364) were to receive milnacipran (100 mg/day) in combination with pregabalin (300 or 450 mg/day) or pregabalin alone, for 11 weeks. The primary endpoint was PGIC responder rate at the end of the study. The study was completed in January 2010 [&lt;ulink linkID="1124451" linkType="Reference"&gt;1124451&lt;/ulink&gt;], [&lt;ulink linkID="1124458" linkType="Reference"&gt;1124458&lt;/ulink&gt;]. In June 2016, data from the trial were presented at the First International Congress on Spinal Pain in South Korea. Patients who had an incomplete response to pregabalin experienced significant pain reduction when milnacipran was adding to the drug regimen [&lt;ulink linkID="1775923" linkType="Reference"&gt;1775923&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2006,  an extension study (MLN-MD-06) was initiated, to evaluate the long-term safety and efficacy of milnacipran in fibromyalgia patients who participated in the MLN-MD-02, -03, and -04 studies. By August 2010, enrollment had been completed but the study was ongoing [&lt;ulink linkID="1124451" linkType="Reference"&gt;1124451&lt;/ulink&gt;]. In November 2011, data were presented from 1227 patients at the ACR/ARHP Annual Meeting in Chicago, IL. Patients treated with milnacipran showed improvement in pain, with a mean decrease from baseline in weekly recall visual analog scale (VAS) pain score of 17.6 mm for the intent to treat population. There were improvements in brief pain inventory scores, global status (Patient Global Impression of Change, Patient Global Disease Status) and physical function (SF36 physical component summary) in milnacipran-treated patients. By month 3, the observed pain improvement was reached and remained constant was reached and was relatively constant throughout the entire study; at the final visit, the weekly recall pain VAS scores improved by 23.9 mm. Similar improvements were observed in weekly recall VAS pain over time from baseline, and remained constant in the two-year cohort (n = 461) and the one-year cohort (n = 820) [&lt;ulink linkID="1231448" linkType="Reference"&gt;1231448&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2006, a randomized, double-blind, placebo-controlled, parallel group, safety and efficacy, phase III trial (&lt;ulink linkID="16105" linkType="Protocol"&gt;NCT00314249&lt;/ulink&gt;; MLN-MD-03) was initiated in subjects (expected n = 1000) with fibromyalgia in the US. The primary endpoint was a composite responder analysis based on pain, patient global status, and physical function. By January 2008 enrollment had been completed [&lt;ulink linkID="678119" linkType="Reference"&gt;678119&lt;/ulink&gt;]. In December 2008, preliminary data were released, by which time 1025 patients had been enrolled. A greater proportion of patients on milnacipran (100 mg/day) experienced at least a 30% reduction in pain from baseline and  rated themselves as "very much improved" or "much improved" based on the patient global assessment scale.   Furthermore, a greater proportion of patients treated with milnacipran showed a treatment response compared to placebo. The drug was generally well tolerated [&lt;ulink linkID="969087" linkType="Reference"&gt;969087&lt;/ulink&gt;]. In October 2009, similar data were reported and subsequently presented at the American College of Rheumatology annual meeting in Philadelphia, PA. Patients were randomly assigned to milnacipran 100 mg/day (n = 516) or placebo (n = 509) and underwent 4 to 6 weeks of flexible dose-escalation, followed by 12 weeks of stable-dose treatment followed by a 2-week randomized, double blinded discontinuation phase. Overall, milnacipran was generally well tolerated and attrition rates in both study groups were similar [&lt;ulink linkID="1050298" linkType="Reference"&gt;1050298&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2006, a multicenter, randomized, double-blind, placebo-controlled, parallel assignment, safety/efficacy study (&lt;ulink linkID="16235" linkType="Protocol"&gt;NCT00436033&lt;/ulink&gt;; F02207GE302) was initiated in subjects (expected n = 824) with fibromyalgia syndrome in Europe. The primary endpoint was efficacy  of milnacipran after 12 weeks of fixed dose exposure. The study was completed in September 2007 [&lt;ulink linkID="955392" linkType="Reference"&gt;955392&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Three phase III trials were initially carried out. In Study &lt;ulink linkID="16104" linkType="Protocol"&gt;NCT00098124&lt;/ulink&gt; (MLN-MD-02), 1196 patients were randomized to receive either milnacipran 100 mg/day (n = 399), 200 mg/day (n = 396) or placebo (n = 401) over a 3-month period; 67.7% completed the trial. In Study FMS-031, 888 patients were randomized to receive either milnacipran 100 mg/day (n = 224), 200 mg/day (n = 441) or placebo (n = 223) for 6 months, 63.6% of whom completed 3 months of treatment, and 57.6% of whom completed the full 6 months of double-blind treatment. Patients who completed the full 6 months of treatment in Study FMS-031 were eligible to enroll in a multicenter, dose-blinded, extension study designed to evaluate durability of response up to 1 year. A total of 449 patients were either maintained at 200 mg/day (n = 209) or re-randomized to 100 mg/day (n = 48) or 200 mg/day (n = 192) for an additional 6 months. In September 2005, Forest and Cypress reported that preliminary top-line results from Study FMS-031 did not achieve statistical significance. However, the FDA subsequently changed its guidelines for approval of fibromyalgia therapies and agreed to allow the companies to re-assess the data based on an updated analysis approach, which included a change from LOCF (last observation carried forward) to BOCF (baseline observation carried forward) analysis as well as other changes in the use of primary endpoints for efficacy evaluation. Using the revised analyses, a daily dose of 200 mg milnacipran produced  significant differences compared to placebo for both the fibromyalgia and pain of fibromyalgia composite endpoints [&lt;ulink linkID="849182" linkType="Reference"&gt;849182&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In Study MLN-MD-02 and Study FMS-031, the two parallel, primary efficacy assessments consisted of composite responder analyses for the treatment of both fibromyalgia and the pain of fibromyalgia. In study FMS-031, at the 3-month visit there were 549 evaluable patients for the syndrome analysis (n = 134 for 100 mg, n = 259 for 200 mg, and n = 156 for placebo), and 553 evaluable patients for the pain analysis (n = 135 for 100 mg,  n = 260 for 200 mg, and n = 158 for placebo). At the 6-month visit there were 488 evaluable patients for the fibromyalgia analysis (n = 120 for 100 mg, n = 229 for 200 mg, and n = 139 for placebo), and 491 evaluable patients for the fibromyalgia pain analysis (n = 121 for 100 mg, n = 230 for 200 mg, and n = 140 for placebo). A  significant number of patients treated with milnacipran       during Study MLN-MD-02 met the composite syndrome responder criteria       (25% and 26% for the milnacipran 100 mg and 200 mg groups,       respectively), compared to patients treated with placebo (13%).     A  significant number of patients treated with milnacipran       during Study FMS-031 also met the composite syndrome responder criteria       at 3 months (33% and 33% for the milnacipran 100 mg and 200 mg       groups, respectively) compared to patients treated with placebo (17%).       Significant differences were also observed at the 6-       month visit: 33% and 32% of patients met responder criteria for the       milnacipran 100 mg and 200 mg groups, respectively, compared to 19% of       patients in the placebo group. For the composite pain responder criteria, a  significant number of patients treated with milnacipran       during Study MLN-MD-02 met the criteria (39%       and 46% in the milnacipran 100 mg and 200 mg groups, respectively),       compared to patients treated with placebo (25%).     A  significant number of patients treated with milnacipran       during Study FMS-031 also met the composite pain responder criteria at       three months (45% and 45% in the milnacipran 100 mg and 200 mg groups,       respectively), compared to patients treated with placebo (27%).       Significant differences were also observed at the 6-month visit: 44% and 45% of patients met the composite pain responder       criteria in the milnacipran 100 mg and 200 mg groups, respectively,       compared to 28% of patients in placebo group [&lt;ulink linkID="849182" linkType="Reference"&gt;849182&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2003, Cypress reported that trial design issues had been resolved with the FDA [&lt;ulink linkID="509879" linkType="reference"&gt;509879&lt;/ulink&gt;], and the trial began shortly afterwards [&lt;ulink linkID="523789" linkType="reference"&gt;523789&lt;/ulink&gt;]. This multiple double-blind, placebo-controlled flexible dose-escalation monotherapy phase III trial was anticipated to be completed in 2006. The trial was designed to investigate the efficacy and safety of the drug for the treatment of pain and associated symptoms such as fatigue and depressed mood [&lt;ulink linkID="518710" linkType="reference"&gt;518710&lt;/ulink&gt;], [&lt;ulink linkID="523789" linkType="reference"&gt;523789&lt;/ulink&gt;]. In December 2004, enrollment was completed [&lt;ulink linkID="575117" linkType="Reference"&gt;575117&lt;/ulink&gt;]. In September 2005, results were released. The primary endpoint of the 888-patient study was a composite of an assessment of pain and a measure of fatigue and depressed mood. Using the last observation carry-forward analysis, the primary endpoint was missed at 3  and 6 months. Using the baseline observation carry-forward (BOCF) method, the primary endpoint was achieved at 3 months, but not at 6 months. Despite this, the FDA may not have accepted the BOCF analysis as satisfying the conditions of a registration study [&lt;ulink linkID="625736" linkType="Reference"&gt;625736&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2001, Cypress filed an IND with the FDA to begin a phase II trial for the treatment of fibromyalgia [&lt;ulink linkID="432543" linkType="reference"&gt;432543&lt;/ulink&gt;]. In January 2002, the company received approval to initiate a double-blind, placebo-controlled, flexible dose escalation monotherapy trial [&lt;ulink linkID="434998" linkType="reference"&gt;434998&lt;/ulink&gt;], [&lt;ulink linkID="437451" linkType="reference"&gt;437451&lt;/ulink&gt;], and in February 2002, began its phase II program. Patients were randomized to receive placebo or milnacipran (qd or bid) for 4 weeks of dose escalation, followed by 8 weeks of constant dose. The study evaluated milnacipran for the treatment of pain and associated symptoms such as fatigue, depressed mood and poor sleep quality [&lt;ulink linkID="441196" linkType="reference"&gt;441196&lt;/ulink&gt;]. In September 2002, Cypress completed enrollment after recruiting fewer than the planned 200 patients, because the number of patients in the 200 mg/day (maximum dose being evaluated) group was already sufficient to allow the company to evaluate efficacy and safety [&lt;ulink linkID="463471" linkType="reference"&gt;463471&lt;/ulink&gt;], [&lt;ulink linkID="469563" linkType="reference"&gt;469563&lt;/ulink&gt;]. In December 2002, a preliminary analysis indicated  significant improvements in pain compared to placebo. Of the 95 patients that had completed the trial as of the date of this analysis, 87% of milnacipran-treated patients reported overall improvement, compared to 33% in the placebo group [&lt;ulink linkID="473677" linkType="reference"&gt;473677&lt;/ulink&gt;]. In February 2003, Cypress reported final results. Milnacipran-treated patients randomized to the bid-dosing group showed significant improvements in pain, compared to those who received placebo. Of all milnacipran-treated patients, 70% reported overall improvement, compared to 36% in the placebo group. Furthermore, 37% of milnacipran bid-treated patients reported at least a 50% reduction in pain intensity, significantly more than the 14% of patients who received placebo. Milnacipran-treated patients also showed improvements in fatigue and depressed mood [&lt;ulink linkID="478348" linkType="reference"&gt;478348&lt;/ulink&gt;]. In May 2003,  similar results were presented at the New Clinical Drug Evaluation Unit meeting in Boca Raton, FL [&lt;ulink linkID="491214" linkType="reference"&gt;491214&lt;/ulink&gt;]. Milnacipran was equally effective in reducing pain for both depressed and non-depressed patients [&lt;ulink linkID="516902" linkType="reference"&gt;516902&lt;/ulink&gt;]. In October 2003, similar results were presented at the American College of Rheumatology &amp;amp; Association of Rheumatology Health Professionals Annual Scientific Meeting in  Orlando, FL [&lt;ulink linkID="510652" linkType="reference"&gt;510652&lt;/ulink&gt;]. In June 2004, similar results were presented at the 24th CINP congress in Paris, France [&lt;ulink linkID="545660" linkType="reference"&gt;545660&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pain&lt;/subtitle&gt;In August 2014, data were published from a trial (&lt;ulink linkID="107334" linkType="Protocol"&gt;NCT01777581&lt;/ulink&gt;) assessing milnacipran in reducing chronic radicular pain in patients (n = 11) with lumbosacral disc disease, demonstrating that milnacipran significantly reduced radicular pain and nociceptive low back pain compared to placebo [&lt;ulink linkID="1639319" linkType="Reference"&gt;1639319&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, a randomized, double-blind, placebo-controlled, parallel-assignment, phase IV trial (&lt;ulink linkID="76083" linkType="Protocol"&gt;NCT01329406&lt;/ulink&gt;; FRX001-2010) was planned in patients (expected n = 50) in the US with pain due to osteoarthritis. The primary endpoint was time to loss of efficacy. At that time, the trial was estimated to complete in September 2012. However, no further development has been reported for this trial [&lt;ulink linkID="1199984" linkType="Reference"&gt;1199984&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2010, a randomized, double-blind, placebo-controlled, parallel group,  trial (&lt;ulink linkID="74437" linkType="Protocol"&gt;NCT01288937&lt;/ulink&gt;) was initiated in the US to evaluate the safety and efficacy of milnacipran as a treatment for patients (expected n = 52) with idiopathic neuropathic pain. The primary endpoint was the mean change in 11 point Likert pain scale over a 9-week treatment period. However, in December 2016, the trial was terminated due to poor enrollment [&lt;ulink linkID="1175425" linkType="Reference"&gt;1175425&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2010, a randomized, double-blind, placebo-controlled, parallel group, phase II study (&lt;ulink linkID="71450" linkType="Protocol"&gt;NCT01225068&lt;/ulink&gt;; STU00036897) was initiated in the US to evaluate the safety and efficacy of milnacipran in treating patients (expected n = 40) with chronic neuropathic low back pain. The primary endpoint was effect size of the pain outcome measures over a 6-week treatment period. In January 2012, the study was completed. In september 2013, results were posted showing that the effect size of VAS painÂ was 31.3 for milnacipram, versus  24.8 for placebo  [&lt;ulink linkID="1175401" linkType="Reference"&gt;1175401&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2010, an uncontrolled, open-label, single group, phase III study (&lt;ulink linkID="71336" linkType="Protocol"&gt;NCT01221740&lt;/ulink&gt;) was initiated in the US to assess the effect of milnacipran as a treatment on the quality of life in back pain patients (expected n = 66). The primary endpoint was the decrease in back pain on the Brief Pain Inventory scale over a 10-week treatment period.  However, in January 2017, the trial was withdrawn with no patients enrolled [&lt;ulink linkID="1175415" linkType="Reference"&gt;1175415&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Irritable bowel syndrome&lt;/subtitle&gt;In November 2011, a randomized, double-blind, placebo-controlled phase II trial (&lt;ulink linkID="82429" linkType="Protocol"&gt;NCT01471379&lt;/ulink&gt;) began  to assess the efficacy of milnacipran in the treatment of IBS in patients who had not previously used SSRI antidepressants. The primary outcome was pain response at 12 weeks. The trial was to enroll 60 patients and complete in April 2013. By November 2013, the study had been terminated due to recruitment difficulties  [&lt;ulink linkID="1340951" linkType="Reference"&gt;1340951&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Depression&lt;/subtitle&gt;Milnacipran had been compared to tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) in over 2400 patients with major depressive disorders. The results suggested that milnacipran offered clinical advantages over TCAs in terms of tolerability and over SSRIs in terms of efficacy [&lt;ulink linkID="274587" linkType="reference"&gt;274587&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2003, preclinical data were presented at the 33rd Neuroscience meeting in New Orleans, LA. Milnacipran was compared to &lt;ulink linkID="2822" linkType="Drug"&gt;citalopram&lt;/ulink&gt; in mice, to investigate differences of effect caused by the background strain. In the forced swim test, citalopram potently and dose-dependently increased immobility in 12956/SvEv mice (almost complete immobility of 45 mg/kg), while no effect on motor activity was observed. Milnacipran dose-dependently decreased immobility in both 12956/SvEv and C57BL/6J, although it was less potent in the former [&lt;ulink linkID="512249" linkType="reference"&gt;512249&lt;/ulink&gt;]. Administration of milnacipran (10 and 30 mg/kg, ip) to anesthetized rats increased extracellular 5-HT and noradrenaline levels in the hippocampus, enhanced synaptic efficacy in the CA1 and suppressed LTP. The suppression of LTP induction was reversed by pretreatment with &lt;ulink linkID="8350" linkType="Drug"&gt;WAY-100635&lt;/ulink&gt; (5-HT1A receptor antagonist; 0.1 mg/kg) or prazosin (alpha1-adrenoceptor antagonist; 10 microg) [&lt;ulink linkID="512247" linkType="reference"&gt;512247&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2003,  data were presented at the 58th Annual Meeting of the Society of Biological Psychiatry in San Francisco, CA, showing that milnacipran effects an enhanced cognitive performance. Milnacipran significantly improved all aspects of the Morris water maze assay performance in mice. Celexa (&lt;ulink linkID="2822" linkType="Drug"&gt;citalopram&lt;/ulink&gt;) did not affect learning performance in mice at the doses tested [&lt;ulink linkID="490078" linkType="reference"&gt;490078&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2002, preclinical data were presented at the 32nd Neuroscience meeting in Orlando, FL. While milnacipran and &lt;ulink linkID="5907" linkType="Drug"&gt;duloxetine&lt;/ulink&gt; were both shown to block the reuptake of serotonin and norepinephrine (NE) when tested against cloned human transport proteins, only milnacipran preferentially blocked the reuptake of NE. Milnacipran was also shown to be a low-affinity NMDA antagonist [&lt;ulink linkID="469563" linkType="reference"&gt;469563&lt;/ulink&gt;], [&lt;ulink linkID="474318" linkType="reference"&gt;474318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2002, Cypress presented data at the American Society of Regional Anesthesia and Pain Medicine meeting in Phoenix, AZ, demonstrating the effectiveness of milnacipran in an animal model of visceral pain. The goal of the experiments presented, was to evaluate the analgesic property of milnacipran on visceral pain in rats, using a colorectal distention model (CRD). Intravenous milnacipran produced significant inhibition of CRD-evoked reflex activity, suggesting it may have a potential application for the treatment of acute visceral pain [&lt;ulink linkID="469767" linkType="reference"&gt;469767&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the forced swimming test in rats and mice, milnacipran (30 to 60 mg/kg, po) significantly decreased the duration of immobility [&lt;ulink linkID="364816" linkType="reference"&gt;364816&lt;/ulink&gt;], [&lt;ulink linkID="469283" linkType="reference"&gt;469283&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the rat learned-helplessness test, animals were subjected to 15 s of uncontrollable electric shocks through the floor every minute for 1 h. They were then given milnacipran at doses of 2, 5, 10 and 20 mg/kg/h (daily dose) for the following 4 days. On day 3, animals were placed in a shuttle box and an avoidance test was performed with 30 stimulus shock trials for a period of 15 min. Milnacipran at the lower doses of 2 and 5 mg/kg helped to reverse the inability of these animals to escape [&lt;ulink linkID="190241" linkType="reference"&gt;190241&lt;/ulink&gt;]. Milnacipran is also an NMDA antagonist [&lt;ulink linkID="227521" linkType="reference"&gt;227521&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In May 2013, Forest stated that the manufacturing facilities in the Republic of Ireland were the exclusive qualified manufacturing facilities for the finished dosage form of milnacipran [&lt;ulink linkID="1429241" linkType="Reference"&gt;1429241&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2004, Pierre Fabre was planning to set up a second production facility for milnacipran in France to support a potential launch in the US market. The site was expected to be operational in 2008 [&lt;ulink linkID="549788" linkType="Reference"&gt;549788&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2002, &lt;ulink linkID="30003" linkType="Company"&gt;Collegium Pharmaceuticals&lt;/ulink&gt; entered into an agreement with Cypress  to develop novel formulations and analogs of milnacipran [&lt;ulink linkID="463170" linkType="reference"&gt;463170&lt;/ulink&gt;]. In January 2004, Cypress exercised its option to license this patent portfolio [&lt;ulink linkID="520076" linkType="reference"&gt;520076&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Dr Kevin Fone, &lt;ulink linkType="Company" linkID="20640"&gt;Nottingham University&lt;/ulink&gt;, UK&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;12 March 1998&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="4858"&gt;Milnacipran&lt;/ulink&gt; (formerly midalcipran, F-2207) is a tertiary amine of cyclopropanecarboxylic acid [&lt;ulink linkType="reference" linkID="204337"&gt;204337&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="204338"&gt;204338&lt;/ulink&gt;], which is structurally unrelated to either the tricyclic antidepressants (TCAs) or the monoamine oxidase inhibitors (MAOIs), except for the non-selective MAOI tranylcypromine. The (Z) enantiomer is the active form of the compound, while the (E) enantiomer does not inhibit the reuptake of monoamines.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="4858"&gt;Milnacipran&lt;/ulink&gt; has approximately twice the potency at inhibiting norepinephrine than serotonin reuptake (IC50 = 100 and 203 nM, respectively in the rat hypothalamus in vitro) and negligible effect on the dopamine transporter [&lt;ulink linkType="reference" linkID="1777"&gt;1777&lt;/ulink&gt;]. Interestingly, autoradiography shows that 3H-&lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; binding in rat brain is potently displaced by SSRIs and the 5-HT neurotoxin 5,7-DHT, but unaffected by the noradrenergic neurotoxin DSP-4 which reduced brain norepinephrine by &amp;lt; 80%, suggesting the most binding may be to the 5-HT transporter at the dose used in this species [&lt;ulink linkType="reference" linkID="281000"&gt;281000&lt;/ulink&gt;]. However, acute administration of &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; increases extracellular levels of both 5-HT and norepinephrine measured by intracerebral microdialysis in the rat [&lt;ulink linkType="reference" linkID="230676"&gt;230676&lt;/ulink&gt;], consistent with inhibition of reuptake of both neurotransmitters. In ligand binding studies &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; is without affinity for a large array of monoamine receptors including, muscarinic, H1, alpha- and beta-adrenoceptors, 5-HT1-like or 5-HT2, or dopamine receptors [&lt;ulink linkType="reference" linkID="230676"&gt;230676&lt;/ulink&gt;]. However, &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; has been reported to be a non-competitive NMDA receptor antagonist both in ligand binding [&lt;ulink linkType="reference" linkID="227521"&gt;227521&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="204337"&gt;204337&lt;/ulink&gt;] and in vivo by protecting mice against NMDA-induced lethality [&lt;ulink linkType="reference" linkID="257769"&gt;257769&lt;/ulink&gt;]. Neither does it have any affinity for benzodiazepine or opiate receptors and it dos not inhibit MAO A or B activity [&lt;ulink linkType="reference" linkID="1777"&gt;1777&lt;/ulink&gt;]. Furthermore, after chronic administration for 3 to 6 weeks in rats, there is no alteration in either the affinity or density of alpha- and beta-adrenoceptors, 5-HT1-like or 5-HT2, or dopamine receptors [&lt;ulink linkType="reference" linkID="1767"&gt;1767&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="94690"&gt;94690&lt;/ulink&gt;] nor in the beta-adrenoceptor agonist-stimulated adenylate cyclase activity in the rat cerebral cortex [&lt;ulink linkType="reference" linkID="227707"&gt;227707&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="123693"&gt;123693&lt;/ulink&gt;]. The absence of beta-adrenoceptor agonist-stimulated adenylate cyclase activity in the rat cerebral cortex [&lt;ulink linkType="reference" linkID="27707"&gt;27707&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="123693"&gt;123693&lt;/ulink&gt;]. The absence of beta-adrenoceptor down-regulation is particularly noteworthy since this was a candidate for the action first generation antidepressants but does not occur with SNRIs or SSRIs  (expect &lt;ulink linkType="Drug" linkID="15183"&gt;sertraline&lt;/ulink&gt;). Acute administration of &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; causes an equivalent dose-dependent reduction in the synthesis of both 5-HT and norepinephrine in the rat frontoparietal cortex estimated by determining the accumulation of the respective precursors, 5-hydroxytryptophan and DOPA, following inhibition of aromatic amino acid decarboxylase [&lt;ulink linkType="reference" linkID="112521"&gt;112521&lt;/ulink&gt;]. In contrast, in the same study, chronic administration of &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; was shown to enhance basal synthesis of both neurotransmitters [&lt;ulink linkType="reference" linkID="112521"&gt;112521&lt;/ulink&gt;]. However, there was no alteration in the uptake of either 5-HT or norepinephrine into rat cortical homogenates following six weeks administration (15 mg/kg/day) in rats [&lt;ulink linkType="reference" linkID="1767"&gt;1767&lt;/ulink&gt;], demonstrating a lack of adaptive changes in monoamine reuptake following chronic administration, despite facilitation of synaptic 5-HT and norepinephrine levels. Three weeks treatment of rats with &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; (50 mg/kg/day) failed to alter the 5-HT agonist-induced release of 3H-serotonin from rat hypothalamus, suggesting that it had not produced 5-HT1A autoreceptor down-regulation [&lt;ulink linkType="reference" linkID="1673"&gt;1673&lt;/ulink&gt;], which is thought to be required for the onset of antidepressant action with SSRIs. Yet like SSRIs, &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; has been shown to suppress the firing of raphe neurons following as little as 2 days administration, probably due to increase in synaptic 5-HT levels [&lt;ulink linkType="Reference" linkID="196861"&gt;196861&lt;/ulink&gt;] firing returns to pre-drug rate after 2 weeks further treatment and is, therefore, likely to be related to the therapeutic effect. In preclinical studies in a rat model to examine anxiety-related behavior, acute &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; administration attenuated conditioned stress freezing behavior, indicative of anxiolytic-like activity [&lt;ulink linkType="reference" linkID="200856"&gt;200856&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="257778"&gt;257778&lt;/ulink&gt;]. In three other paradigms commonly used to assess potential antidepressant activity, the behavioral despair (Porsolt) and bulbectomized rat [&lt;ulink linkType="reference" linkID="257773"&gt;257773&lt;/ulink&gt;] and [&lt;ulink linkType="reference" linkID="257778"&gt;257778&lt;/ulink&gt;] and the forced swim paradigm in mice [&lt;ulink linkType="reference" linkID="230676"&gt;230676&lt;/ulink&gt;], milancipran was active at 3 to 30 mg/kg po. Although such animal tests of depression are only able to assess drug action on activity that is designed to emulate specific aspects of the disease, few false positives would be expected in four separate animal models.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;Unlike related SNRIs &lt;ulink linkType="Drug" linkID="5907"&gt;duloxetine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4648"&gt;venlafaxine&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; lacks any active metabolites [&lt;ulink linkType="reference" linkID="196861"&gt;196861&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="4858"&gt;Milnacipran&lt;/ulink&gt; is rapidly absorbed and has a bioavailability of approximately 85%, low plasma protein binding and is excreted in the urine both as parent drug (50%) and inactive metabolites (40%) principally as glucuronide [&lt;ulink linkType="reference" linkID="230670"&gt;230670&lt;/ulink&gt;]. In patients the plasma half-life is between 5.8 and 8.1 h, although a longer half-life and elevated plasma concentration has been reported probably associated with a decrease in renal function [&lt;ulink linkType="reference" linkID="1605"&gt;1605&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;In guinea pigs &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; was shown to have a better safety index in terms of its depressant effect on the ventricular myocardium than imipramine [&lt;ulink linkType="reference" linkID="1774"&gt;1774&lt;/ulink&gt;]. At clinical doses of 200 to 300 mg/day side-effects were produced by &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; are low in incidence compared with TCAs and MAOIs [&lt;ulink linkType="reference" linkID="1766"&gt;1766&lt;/ulink&gt;]. The preferred dose of 50 mg twice daily is better tolerated than 100 mg twice a day. Meta-analysis [&lt;ulink linkType="reference" linkID="257770"&gt;257770&lt;/ulink&gt;] shows that at this dose drop-outs due to side-effects are 6.1% with placebo (n = 394), 7.6% with &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; (n = 1871), 14.8% with TCAs (n = 940) and 7.8% with SSRIs (n=344). The most common untoward responses are dry mouth, constipation, headache, hypotension and nausea or vomiting [&lt;ulink linkType="reference" linkID="274587"&gt;274587&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="230625"&gt;230625&lt;/ulink&gt;]. However, in meta-analysis the only side-effects noted with a greater frequency in the &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; compared to the placebo group were vertigo, increased sweating, anxiety, hot flushes and dysuria [&lt;ulink linkType="reference" linkID="257770"&gt;257770&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="4858"&gt;Milnacipran&lt;/ulink&gt; is also associated with less nausea and vomiting than SSRIs (&lt;ulink linkType="Drug" linkID="17558"&gt;fluoxetine&lt;/ulink&gt; and fluvoxetine) but is accompanied by a higher incidence of headache, dry mouth and dysuria [&lt;ulink linkType="reference" linkID="230625"&gt;230625&lt;/ulink&gt;]. Most adverse effects are observed in the first three months and decrease in incidence thereafter. In fifteen reported cases of deliberate overdose (ingestion of up to 2800 mg) there have been no fatalities, which probably reflects the absence of cardiotoxic effects with &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt;, which is particularly beneficial when compared with the TCAs [&lt;ulink linkType="reference" linkID="257770"&gt;257770&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;In early double-blind trials in 58 in patients with major depressive disorder, &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; (50 mg 2x/day) produced significant improvements compared with placebo as early as 14 days after onset [&lt;ulink linkType="reference" linkID="1770"&gt;1770&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="257770"&gt;257770&lt;/ulink&gt;] and in a similar group of patients &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; (200 mg/day) was found to be at least as efficacious as amitriptyline (150 mg/day) [&lt;ulink linkType="reference" linkID="1772"&gt;1772&lt;/ulink&gt;] and clomipramine [&lt;ulink linkType="reference" linkID="55462"&gt;55462&lt;/ulink&gt;]. From meta-analysis of original pooled data the minimal clinically effective dose would appear to be 50 mg 2x/day and form the results of six trials of comparable design (2 x 75 mg or 2 x 50 mg/day) against imipramine in 726 patients with depression &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; was shown to be at least as effective as TCA, imipramine, but significantly better tolerance  (7.6% compared with 14.8% withdrawal with TCA) [&lt;ulink linkType="reference" linkID="257770"&gt;257770&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="230663"&gt;230663&lt;/ulink&gt;]. In a total of 2462 patients with major depressive disorder &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; (50 mg twice daily) produced a significantly higher response rate than SSRIs (clinical global impression scores being 2.64 compared with 2.32, p &amp;lt; 0.05) with a similar adverse event profile [&lt;ulink linkType="reference" linkID="274587"&gt;274587&lt;/ulink&gt;]. At the optimal dose (2x 50 mg) the response rate to &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; (65%) is equivalent to both TCAs and SSRIs [&lt;ulink linkType="reference" linkID="274587"&gt;274587&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="4858"&gt;Milnacipran&lt;/ulink&gt; is a mixed serotonin/norepinephrine reuptake inhibitor (SNRI, inhibiting reuptake of both serotonin and norepinephrine) which has no significant affinity for any neurotransmitter receptor (except NMDA) and is in phase III clinical trials for the treatment of major depression. It is likely to prove beneficial in this highly competitive market since a reduced incidence of cholinergic side-effects compared with TCAs and a reduced frequency of nausea and anxiety compared with SSRIs appears to be a reproducible finding. Despite the fact that there are a large number of antidepressants currently available, new drugs with improved therapeutic safety and tolerability which can be used in both elderly patients and those with cardiac, renal or hepatic disease are still required, &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; could also be superior to previous antidepressants in this area. The overall pharmacokinetic profile of &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; (good bioavailability, low plasma protein binding and excretion in the urine largely as parent drug) support the contention that drug interactions are likely to be minimal with this compound. The SNRIs, such as &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt;, are largely devoid of the adverse side-effects associated with the first generation antidepressants (TCAs and MAOIs) but share their efficacy. The lack of side-effects is probably due to a lack of any direct interaction with monamine receptors (principally for norepinephrine and acetylcholine and histamine) and results in a better patient compliance than with TCAs and comparable tolerability to the SSRIs. There is conflicting evidence as to whether &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; has a more rapid onset of therapeutic benefit than earlier antidepressants and given the difficulty of assessing the onset of amelioration of symptoms a more detailed investigation of this specific point is required before this can be verified. In any case the earlier onset of action may simply result from the ability to give a higher doses of &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt; than earlier generation antidepressants as a consequence of the lower incidence of adverse effects. There is increasing evidence that the SNRI, &lt;ulink linkType="Drug" linkID="4858"&gt;milnacipran&lt;/ulink&gt;, may have superior efficacy to SSRIs in-patients with severe depression and more clinical trials to assess this and its role in resistant depression are clearly warranted. &lt;br/&gt;	&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17408">Janssen Pharmaceutical KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2000-10-05T00:00:00.000Z</StatusDate><Source id="1254721" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15280">Bukwang Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2001-02-28T00:00:00.000Z</StatusDate><Source id="1048441" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14303">Asahi Kasei Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2000-10-05T00:00:00.000Z</StatusDate><Source id="1254721" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1999-05-31T00:00:00.000Z</StatusDate><Source id="1048441" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1999-04-30T00:00:00.000Z</StatusDate><Source id="1048441" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="XC">North Africa</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2000-08-31T00:00:00.000Z</StatusDate><Source id="1048441" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="XF">Central America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2001-04-30T00:00:00.000Z</StatusDate><Source id="1048441" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2014-07-01T00:00:00.000Z</StatusDate><Source id="1574106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1997-06-19T00:00:00.000Z</StatusDate><Source id="1346524" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2017-07-31T00:00:00.000Z</StatusDate><Source id="2065992" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1996-12-06T00:00:00.000Z</StatusDate><Source id="1450303" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1999-04-30T00:00:00.000Z</StatusDate><Source id="1048441" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17408">Janssen Pharmaceutical KK</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2011-12-31T00:00:00.000Z</StatusDate><Source id="1548001" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2003-04-30T00:00:00.000Z</StatusDate><Source id="1048441" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2014-07-01T00:00:00.000Z</StatusDate><Source id="1574106" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26494">Sanofi-Synthelabo</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate>2001-02-01T00:00:00.000Z</StatusDate><Source id="413342" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17403">Janssen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2527">Fibromyalgia</Indication><StatusDate>2012-03-30T00:00:00.000Z</StatusDate><Source id="1277060" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16198">Forest Laboratories Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="192">Irritable bowel syndrome</Indication><StatusDate>2013-11-30T00:00:00.000Z</StatusDate><Source id="1340951" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26494">Sanofi-Synthelabo</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate>2001-02-01T00:00:00.000Z</StatusDate><Source id="413342" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353365" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19087">Pierre Fabre SA</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2008-02-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3221">Back pain</Indication><StatusDate>2018-07-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate>2018-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23891">Cypress Bioscience Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2010-08-04T00:00:00.000Z</StatusDate><Source id="1121367" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17408">Janssen Pharmaceutical KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2000-09-28T00:00:00.000Z</StatusDate><Source id="383727" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17403">Janssen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2010-11-11T00:00:00.000Z</StatusDate><Source id="1147545" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19087">Pierre Fabre SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2008-06-30T00:00:00.000Z</StatusDate><Source id="955405" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19087">Pierre Fabre SA</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1996-12-06T00:00:00.000Z</StatusDate><Source id="1346524" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14303">Asahi Kasei Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1999-11-29T00:00:00.000Z</StatusDate><Source id="348868" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16198">Forest Laboratories Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="192">Irritable bowel syndrome</Indication><StatusDate>2011-11-15T00:00:00.000Z</StatusDate><Source id="1340951" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16198">Forest Laboratories Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3221">Back pain</Indication><StatusDate>2010-08-31T00:00:00.000Z</StatusDate><Source id="1175415" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16198">Forest Laboratories Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate>2010-11-30T00:00:00.000Z</StatusDate><Source id="1175425" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16198">Forest Laboratories Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2012-03-30T00:00:00.000Z</StatusDate><Source id="1277060" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16198">Forest Laboratories Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2009-04-30T00:00:00.000Z</StatusDate><Source id="1008295" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23891">Cypress Bioscience Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2002-02-13T00:00:00.000Z</StatusDate><Source id="441196" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23891">Cypress Bioscience Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2001-08-03T00:00:00.000Z</StatusDate><Source id="417632" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19087">Pierre Fabre SA</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1996-12-06T00:00:00.000Z</StatusDate><Source id="1450303" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3221">Back pain</Indication><StatusDate>2014-07-01T00:00:00.000Z</StatusDate><Source id="1574106" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1088700">Allergan plc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="1295">Neuropathic pain</Indication><StatusDate>2014-07-01T00:00:00.000Z</StatusDate><Source id="1574106" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19087">Pierre Fabre SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2011-11-21T00:00:00.000Z</StatusDate><Source id="1241781" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1999-11-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1999-11-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23891">Cypress Bioscience Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2003-10-07T00:00:00.000Z</StatusDate><Source id="523789" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16198">Forest Laboratories Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2004-01-09T00:00:00.000Z</StatusDate><Source id="518710" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19087">Pierre Fabre SA</Company><Country id="FR">France</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="93">Depression</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19087">Pierre Fabre SA</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1997-09-26T00:00:00.000Z</StatusDate><Source id="264142" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19087">Pierre Fabre SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2006-02-15T00:00:00.000Z</StatusDate><Source id="955392" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23891">Cypress Bioscience Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="864011" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16198">Forest Laboratories Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="864011" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16198">Forest Laboratories Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2009-01-14T00:00:00.000Z</StatusDate><Source id="976636" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23891">Cypress Bioscience Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2009-01-14T00:00:00.000Z</StatusDate><Source id="976636" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26495">Sanofi (pre-1999)</Company><Country id="XE">South America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1998-03-01T00:00:00.000Z</StatusDate><Source id="291369" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26495">Sanofi (pre-1999)</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1998-03-01T00:00:00.000Z</StatusDate><Source id="291369" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23891">Cypress Bioscience Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2527">Fibromyalgia</Indication><StatusDate>2009-04-30T00:00:00.000Z</StatusDate><Source id="1008295" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1022453">Asahi Kasei Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1088700">Allergan plc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="15280">Bukwang Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="19087">Pierre Fabre SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="30003">Collegium Pharmaceutical Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="DOL1000090">Royalty Pharma</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="17">Patent - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>3</CountActive><CountInactive>1</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>2</CountActive><CountInactive>1</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="8">Technology - Delivery/Formulation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)c2ccccc2.Cl</Smiles><Smiles>CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)c2ccccc2</Smiles></StructureSmiles><Deals><Deal id="105286" title="Forest Laboratories to develop Cypress Bioscience's milnacipran for fibromyalgia syndrome in the US"/><Deal id="112147" title="Cypress Bioscience to develop and market bioMerieux-Pierre Fabre's milnacipran in North America for myalgia        "/><Deal id="118258" title="Asahi to market Pierre Fabre's milnacipran in Japan"/><Deal id="118260" title="Synthelabo to develop Pierre Fabre's milnacipran in certain European, Latin American, and Asian countries"/><Deal id="118261" title="Janssen-Kyowa to market Pierre Fabre's milnacipran in Japan"/><Deal id="118264" title="Collegium and Cypress to codevelop novel formulations and analogs of milnacipran  "/><Deal id="128286" title="Bukwang to commercialize Pierre Fabre's milnacipran in Korea "/><Deal id="133664" title="Janssen to market Bystolic and Savella in Canada from Forest Laboratories     "/><Deal id="186704" title="Purchase of all U.S. and Canadian IP for Bystolic (nebivolol) for hypertension, eliminating all future royalties"/></Deals><PatentFamilies><PatentFamily id="1023983" number="WO-03068211" title="Methods of treating attention deficit/hyperactivity disorder (ADHD)"/><PatentFamily id="1025018" number="WO-2006080555" title="Process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-phthalimidomethylcyclopropane"/><PatentFamily id="1058108" number="FR-02759290" title="Use of milnacipran."/><PatentFamily id="1088053" number="WO-09726256" title="New Process For The Preparation Of Bicyclic Lactones"/><PatentFamily id="1142172" number="WO-2005118564" title="Methods for the synthesis of milnacipran and congeners thereof"/><PatentFamily id="1160433" number="WO-2004105690" title="Treatment of chronic pain associated with drug or radiation therapy"/><PatentFamily id="1161533" number="WO-2007034990" title="Novel combination of drugs as antidepressant"/><PatentFamily id="1188006" number="WO-2012028922" title="Controlled release pharmaceutical compositions of milnacipran"/><PatentFamily id="1201657" number="EP-00377381" title="Process for the preparation of 1-phenyl-1-diethyl amino-carbonyl-2-phthalimide methyl cyclopropane z."/><PatentFamily id="1237050" number="WO-09808495" title="Galenic formula with extended release of milnacipran."/><PatentFamily id="1263532" number="WO-2011107922" title="Extended release composition of milnacipran"/><PatentFamily id="126508" number="WO-09735574" title="Composition containing milnacipran and idazoxan for use as a combined pharmaceutical preparation."/><PatentFamily id="1275591" number="EP-00200638" title="Process for the preparation of (Z)-1-phenyl-1-diethyl amino carbonyl 2-amino methyl cyclopropane hydrochloride"/><PatentFamily id="1298168" number="JP-03797605" title="The manufacturing method of a granular coating|coated formulation"/><PatentFamily id="1315429" number="WO-2012059933" title="A new process for preparing optically pure milnacipran and its pharmaceutically acceptable salts."/><PatentFamily id="1344893" number="EP-00068999" title="Derivatives of 1-aryl-2-aminomethyl-cyclopropane-carboxamides (Z), their preparation and their use as medicines in the treatment of disorders of the central nervous system."/><PatentFamily id="1362333" number="WO-2004009069" title="Treatment of depression secondary to pain (dsp)"/><PatentFamily id="1362892" number="WO-2004045718" title="Treatment of cognitive dysfunctions"/><PatentFamily id="1436363" number="WO-03039598" title="Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatique syndrome and pain"/><PatentFamily id="1529816" number="US-20100197797" title="Methods of managing fibromyalgia using milnacipran"/><PatentFamily id="1532554" number="WO-2008067752" title="A process for preparing optical pure milnacipran and its pharmaceutically accepted salts"/><PatentFamily id="1547933" number="WO-2008060397" title="Method of treating thermoregulatory disfunction"/><PatentFamily id="1585173" number="WO-2004039320" title="Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof"/><PatentFamily id="1589818" number="WO-2008031928" title="Use of milnacipran for reducing the rewarding properties of alcohol during or after an alcohol withdrawal treatment"/><PatentFamily id="1606327" number="WO-2010036773" title="Deuterated l-aryl-2-aminomethyl cyclopropane carboxyamide derivatives"/><PatentFamily id="1625802" number="US-20100274050" title="Solid milnacipran and process for the preparation of the same"/><PatentFamily id="1658855" number="WO-2004035035" title="Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms"/><PatentFamily id="1664810" number="US-20090069431" title="Deuterium-enriched milnacipran"/><PatentFamily id="1683349" number="WO-03053426" title="Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain"/><PatentFamily id="1709680" number="US-20120184774" title="Process for the preparation of pharmaceutically acceptable salts of racemic milnacipran and its optical enantiomers thereof"/><PatentFamily id="1743647" number="JP-2004292445" title="Antidiabetic"/><PatentFamily id="1785221" number="WO-2012046247" title="Process for the preparation of (Z)-2-(aminomethyl)-N,N-diethyl-L-phenylcyclopropane carboxamide hydrochloride"/><PatentFamily id="1832120" number="WO-2004030633" title="Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders"/><PatentFamily id="1901198" number="WO-03077897" title="Ne and 5-HT reuptake inhibitors for treating visceral pain syndromes"/><PatentFamily id="1935036" number="AU-2012203789" title="Milnacipran for the long-term treatment of fibromyalgia syndrome"/><PatentFamily id="1983434" number="WO-03101443" title="The use of milnacipran for the treatment of tension-type headache"/><PatentFamily id="1985132" number="WO-2007038620" title="Milnacipran for the long-term treatment of fibromyalgia syndrome"/><PatentFamily id="2033085" number="WO-2007098356" title="Congeners of milnacipran as monoamine re-uptake"/><PatentFamily id="2049821" number="WO-2007086493" title="Medicine for transnasal administration"/><PatentFamily id="2081887" number="WO-00057856" title="Fast-Dissolving Isotropic Expanded Microporous Composition Or Structure For Pharmaceutical, Veterinary, Dietetic, Food Or Cosmetic And Use And Method For Obtaining Same"/><PatentFamily id="2225599" number="WO-2011107921" title="Modified release composition of milnacipran"/><PatentFamily id="2251030" number="WO-2004035036" title="A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-HT2a antagonistic activity"/><PatentFamily id="2329615" number="WO-2008021932" title="Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia"/><PatentFamily id="2363575" number="WO-2008019388" title="Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome"/><PatentFamily id="2370578" number="WO-2011016057" title="Controlled release pharmaceutical compositions of milnacipran"/><PatentFamily id="2409086" number="JP-2012193176" title="Pharmaceutical composition for the milnacipran containing percutaneous absorption"/><PatentFamily id="2425493" number="CN-102793683" title="Sustained-release L-milnacipran composition and preparation method"/><PatentFamily id="2473133" number="JP-2013035836" title="The discharge function inhibitor of p glycoprotein"/><PatentFamily id="2491558" number="WO-2013036403" title="Treatment of diseases related to Î±-subunits of sodium channels, voltage-gated (scnxa) with small molecules"/><PatentFamily id="2610810" number="CN-103083274" title="One containing a left rice milnacipran a slow release composition and preparation method thereof"/><PatentFamily id="2631637" number="WO-2013168002" title="Compositions and methods for the treatment of neurological conditions"/><PatentFamily id="2633884" number="IN-00307799" title="Extended release pharmaceutical composition used for treating clinical depression and chronic pain, especially fibromyalgia, comprises milnacipran, wax as rate controlling excipient, and excipient"/><PatentFamily id="2666086" number="WO-2014009767" title="An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (Z) derivatives, their isomers and salts"/><PatentFamily id="2724424" number="CN-103601652" title="Preparation method of the hydrochloric acid milnacipran rice"/><PatentFamily id="2748127" number="CN-103694162" title="(1s, 2r)-1-phenyl-2-(m a sub.) methyl-n, n-diethyl-a c a methane amide is prepared."/><PatentFamily id="3412352" number="IN-201501054" title="Preparation of dextromilnacipran used in analysis of levomilnacipran, involves reacting carboxamide-containing compound with potassium phthalimide and reacting obtained dioxoisoindolin-containing compound with ethanolamine"/><PatentFamily id="4295956" number="CN-108888604" title="A milnacipran timing delayed controlled release osmotic pump controlled release tablet and preparation method thereof"/><PatentFamily id="479627" number="WO-2008015163" title="Treatment of pain"/><PatentFamily id="516054" number="KR-2009103656" title="Fibromyalgia therapeutic agent."/><PatentFamily id="579186" number="WO-2004067039" title="Multiparticulate compositions of milnacipran for oral administration"/><PatentFamily id="667050" number="WO-2011158249" title="Process for preparation of milnacipran intermediate and its use in preparation of pure milnacipran"/><PatentFamily id="716342" number="WO-2004060374" title="Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders."/><PatentFamily id="735597" number="CN-101301283" title="Composite of milnacipran transferred by nose and brain"/><PatentFamily id="775672" number="WO-2008147843" title="Methods for improving physical function in fibromyalgia"/><PatentFamily id="792144" number="WO-2006132307" title="Stabilized milnacipran formulation"/><PatentFamily id="943841" number="WO-09836744" title="Use of minalcipran and its derivatives for preparing a medicine for treating certain psychiatric diseases."/><PatentFamily id="951757" number="WO-03090743" title="Prevention and treatment of functional somatic disorders, including stress-related disorders"/><PatentFamily id="964137" number="WO-2010129689" title="Milnacipran formulations"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>8</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>25</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>24</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sichuan University" id="1003379"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Shyndec Pharmaceutical Co Ltd" id="1015980"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CoNCERT Pharmaceuticals Inc" id="1021896"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Asahi Kasei Corp" id="1022453"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MSN Laboratories Ltd" id="1025511"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Micro Labs Ltd" id="1028350"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arch Group" id="1028753"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Haisen Pharmaceutical Co Ltd" id="1028852"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Otsuka Holdings Co Ltd" id="1040632"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protia LLC" id="1043660"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China National Pharmaceutical Group Corporation" id="1055632"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hainan Kang Hong Pharmaceutical Co Ltd" id="1078423"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hetero Group" id="1087006"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Allergan plc" id="1088700"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Endo International plc" id="1089706"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="K.B. Institute of Pharmaceutical Education &amp; Research" id="1099980"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shenzhen Foncoo Pharmaceutical Co Ltd" id="1106662"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boehringer Ingelheim International GmbH" id="14881"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eisai Co Ltd" id="15872"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hisamitsu Pharmaceutical Co Inc" id="16802"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Neurocrine Biosciences Inc" id="18501"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NeuroSearch A/S" id="18504"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nippon Zoki Pharmaceutical Co Ltd" id="18562"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pierre Fabre SA" id="19087"/><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="OPKO Health Inc" id="21759"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lupin Ltd" id="21932"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Apotex Inc" id="22353"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="St Marianna University School of Medicine" id="26095"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wockhardt Ltd" id="27614"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Glenmark Pharmaceuticals Ltd" id="29326"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Collegium Pharmaceutical Inc" id="30003"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Royalty Pharma" id="DOL1000090"/><CountAsOwner>16</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>17</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></drugRecordOutput>